REpAb® Nanobody Discovery.
Discover functionally validated VHH nanobodies directly from antigen-enriched serum.
Antibody Discovery In Camelids.
How It Works.
Rapid Novor’s REpAb® Nanobody Discovery Service delivers an end-to-end discovery platform for VHH antibodies (nanobodies) directly from antigen-enriched pAb. Unlike conventional library-based methods, REpAb® uses mass spectrometry and advanced bioinformatics to identify and reconstruct full-length VHH sequences that have already undergone in vivo affinity maturation and demonstrated functional relevance in a pAb format.
This service supports biotech and pharmaceutical discovery teams as well as diagnostics developers in accelerating lead identification with high-confidence antibody sequences suitable for downstream engineering, expression, and characterization.
Why Nanobody Discovery Matters.
Camelids such as alpacas and llamas naturally produce heavy-chain-only antibodies. The antigen-binding domain of these antibodies, the VHH, represents a single-domain antibody fragment with unique advantages:
These features make VHHs exceptionally valuable for therapeutic, diagnostic, and research reagent applications.
REpAb® Platform Capabilities.
Application Note: Alpaca VHH Discovery
REpAb® was applied to an antigen-enriched alpaca IgG preparation. Among ten unique heavy-chain-only antibody sequences identified:
- Nine exhibited specific antigen binding upon recombinant expression.
- A subset underwent SPR and HDX-MS characterization, revealing diverse binding kinetics and distinct epitopes across both Fab and Fc regions of the antigen.
This demonstrates the capability of REpAb® to discover high-quality nanobody lead candidates with structural and functional diversity.
Getting Started.
Deliverables
- Full-length, antigen-specific VHH sequences with confidence metrics through peptide datasets.
- Abundance and ranking data to prioritize leads.
- Recombinant expression constructs and expression data (optional).
- Biophysical characterization of recombinant antibodies (optional).
- Technical report summarizing methods, results, and recommended candidates.
Turn-Around Time
Advantages of Protein-First Discovery.
REpAb®targets functional antibodies already present in serum that have undergone natural affinity maturation and selection. This contrasts with traditional VHH discovery workflows that:
Applications
REpAb ® Nanobody Discovery is suitable for:
- Therapeutic Lead Identification
- Diagnostic Reagent Development
- Research Tool Generation
- Epitope-Targeted Engineering Projects
More on How REpAb Works.
Rapid Novor’s REpAb® Nanobody Discovery Service delivers an end-to-end discovery platform for VHH antibodies (nanobodies) directly from antigen-enriched serum. Unlike conventional library-based methods, REpAb® uses protein-first mass spectrometry and advanced bioinformatics to identify and reconstruct full-length VHH sequences that have already undergone in vivo affinity maturation and demonstrated functional relevance.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics
Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.
Talk to Our Scientists.
We Have Sequenced 10,000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
The Science of Antibody Discovery.
Antibody Sequencing & Discovery Services.
Antibody Sequencing, Discovery and Characterization Services.
Antibody Sequencing & Discovery Services.
REmAb® mAb Sequencing
Monoclonal antibody sequencing from small antibody samples, no need for hybridoma or DNA information. Full sequence in record time.
Explore Antibody Sequencing Services
REpAb® pAb Sequencing
Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Explore Antibody Discovery Services
RapidSPR™ Analysis
Label-free evaluation of antibody-antigen binding using surface plasmon resonance on Biacore or Nicoya. Can be employed for detailed kinetic profiling, kinetics screening, or epitope binning.
Explore SPR Services
RapidHDX-MS™
Mass spec based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
Explore HDX-MS Epitope Mapping Service
MATCHmAb™
Antibody verification by rapid peptide mapping. Antibody sequence confirmation and full detailed mapping for development purposes.
Explore Peptide Mapping Service
Antibody Characterization
LC-MS analysis for study of antibody glycosylation, disulfide bonds, post-translational modifications, sequence variants, intact mass and size.
Explore Antibody Characterization Services